Transaction DateRecipientSharesTypePriceValue
5th February 2021Kevin Lee100Open or private sale$31.00$3,100.00
20th January 2021Kevin Lee734Open or private sale$31.33$22,994.16
20th January 2021Kevin Lee351Open or private sale$33.00$11,583.00
20th January 2021Kevin Lee100Open or private sale$32.02$3,202.00
19th January 2021Kevin Lee371Open or private sale$30.22$11,211.36
19th January 2021Kevin Lee100Open or private sale$31.09$3,109.00
19th January 2021Kevin Lee4,529Open or private sale$29.14$131,970.08
15th January 2021Kevin Lee5,000Open or private sale$27.01$135,050.00
14th January 2021Lee Kalowski10,000Exercise of derivative$1.60$16,000.00
14th January 2021Kevin Lee5,000Open or private sale$25.00$125,000.00
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Bicycle Therapeutics Plc engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display platform to identify bicycles.

Ticker: BCYC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1761612
Employees: 72
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags